Mineralys Therapeutics completes enrollment in Explore-CKD Phase 2 trial
Mineralys Therapeutics (MLYS) has completed enrollment in the Explore-CKD Phase 2 trial evaluating the efficacy and safety of lorundrostat for ...
Scientists design an effective treatment strategy to prevent heart injury caused by a class of anticancer drugs
A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with international partners, has designed a strategy for preventing the cardiotoxic ...
Armed robbery in Revesby54m
Scientists Craft Heart-Safe Strategy for Cancer Drugs
A team of scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC), working in collaboration with ...
Neurology Advisor5h
GLP-1 Receptor Agonists Tied to Risks and Benefits Beyond Weight Loss
For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.
New, increasingly widely used diabetes medication may have additional health benefits for older adults
A new and increasingly widely used diabetes medication may have additional health benefits for older adults, according to new ...
New Therapeutic Target Discovered for Lethal Form of Heart Failure
Researchers discovered that ALPK2, a heart-specific enzyme, may protect against HFpEF by activating TPM1 in heart muscle ...
Mineralys completes enrollment for hypertension drug trial
RADNOR, Pa. - Mineralys Therapeutics , Inc. (NASDAQ:MLYS), a biopharmaceutical company specializing in the development of treatments for cardiovascular and kidney diseases, has announced the ...